37 results about "P. multocida" patented technology

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

This invention discloses a method for preparing a bivalent inactivated vaccine against bovine Pasteurella multocida type A and B and hemolytic Mansicular disease, belonging to the field of vaccine technology. The invention involves isolating capsular serum Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease; separately expanding the culture of these bacteria, then inactivating and concentrating the bacterial suspensions, and resuspending them in PBS to prepare bacterial suspensions; and finally, mixing the Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease suspensions with aluminum hydroxide adjuvant to prepare the inactivated vaccine. This invention provides simultaneous prevention of two diseases—bovine fibrinous purulent pneumonia and bovine hemorrhagic septicemia—as well as bovine Mansicular disease through vaccine immunization. The vaccine demonstrates good safety, stable immunization efficacy, and a long duration of immunity.

The invention relates to the technical field of veterinary drug preparation, in particular to a bovine pasteurella multocida capsular group B disease inactivated vaccine and a preparation method thereof. The inactivated vaccine comprises an adjuvant and an antigen, wherein the antigen is a bovine pasteurella multocida capsular group B NM strain; the antigen is a bovine pasteurella multocida capsular group B NM strain which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 5, 2023, and is classified and named as pasteurella multocida with the preservation number of CGMCC No.45600. The bovine pasteurella multocida capsular group B disease inactivated vaccine provided by the invention can generate an effective and stable immune protection effect on immunized cattle when the injection dosage is 2ml. The vaccine does not need to be too high in concentration, is good in safety, does not generate abscess and nodules at an injection part, can be applied to clinic, can achieve 100% protection, is high in adhesion, and provides a good prevention effect on epidemic bovine abortion infectious diseases.

The invention belongs to the technical field of biology, and particularly relates to a quintuple fluorescent PCR detection reagent for porcine respiratory pathogens and application of the quintuple fluorescent PCR detection reagent. The quintuple fluorescent PCR detection reagent disclosed by the invention can achieve the purpose of simultaneously identifying and detecting actinobacillus pleuropneumoniae, haemophilus parasuis, mycoplasma hyopneumoniae, pasteurella multocida and / or streptococcus suis, and has the advantages of simplicity, convenience and rapidness in operation, high accuracy, high sensitivity and good repeatability; the method has important significance on rapid and accurate detection and epidemic disease prevention and control of clinical porcine respiratory pathogens.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Z34B3 and application thereof. The amino acid sequence of the antibacterial peptide Z34B3 provided by the invention is shown as SEQ ID NO: 1, the secondary structure is an alpha helix, the molecular weight is small, and the antibacterial peptide Z34B3 can change the cell membrane permeability of various gram-negative bacteria including pasteurella multocida, escherichia coli and acinetobacter baumannii, inhibit the generation of cell membranes and play antibacterial and bactericidal roles. Moreover, the antibacterial peptide Z34B3 provided by the invention has low hemolytic activity and no cytotoxicity, and can be applied to preparation of products with bacteriostatic and bactericidal effects and preparation of drugs for preventing and / or treating bacterial infectious diseases. Furthermore, the C tail end of the antibacterial peptide Z34B3 is subjected to amidation modification, and compared with non-modification treatment, the stability can be improved.

The application discloses a kit and method for visual detection of Pasteurella multocida based on CRISPR-Cas12a, wherein the kit is used for amplifying a sample to be detected, then under the mediation of a crRNA guide sequence, a CRISPR-Cas12a system is guided to recognize, combine and cut target double-strand DNA to activate a non-specific nuclease function, then an ssDNA fluorescent probe in the arbitrary cutting system is cut to obtain a cutting product and color development detection is performed to determine. The kit can detect nucleic acid of Pasteurella multocida with a sensitivity of 2 copies per muL, and can select RPA for amplification, and the whole process is performed in a 37 DEG C environment, naked eyes can directly observe, and the dependence on laboratory large instruments is broken, and the purpose of on-site rapid visual detection of target nucleic acid is achieved.

The invention is suitable for the technical field of veterinary biological products, and provides a pasteurella egg yolk antibody for sheep and a preparation method thereof, and the preparation method comprises the following steps: S1, preparing an immunogen; s2, immunizing the hens; s3, crude extraction of an egg yolk antibody: separating egg yolk, collecting egg yolk liquid, adding a PBS buffer solution in proportion to fully dissolve the egg yolk, and standing and centrifuging to obtain a crude extract; s4, egg yolk antibody purification: precipitating the crude body fluid with an ammonium sulfate solution with the saturation degree of 38%, collecting antibody precipitate, dissolving with a PBS buffer solution, carrying out primary dialysis, then adding an ammonium sulfate solution with the saturation degree of 28%, carrying out secondary precipitation, and finally carrying out secondary dialysis to obtain a purified egg yolk antibody solution; and S5, antibody quality detection and split charging. The scheme has the advantages of comprehensive serotype coverage and strong protective force; the original animal is used for separating strains, so that the specificity is high; and the antibody has the advantages of high purity, low side reaction rate, quick response, no drug resistance, no residue and the like, and can be applied to prevention and treatment.

This invention discloses a PKPD-guided method for treating porcine Pasteurella multocida with antibiotics. YDMS injection is used as the antibiotic, administered intramuscularly to pigs infected with Pasteurella multocida. The dosing regimen is adjusted based on in vivo PK / PD target values. The minimum inhibitory concentration (MIC) of YDMS against Pasteurella multocida is 0.06 μg / mL. PK / PD monitoring is performed using a combination of colloidal gold rapid detection and quantitative real-time PCR. This invention clarifies the three-level PK / PD target values ​​of YDMS against Pasteurella multocida and uses AUIC as the core quantitative indicator, avoiding the blindness of traditional empirical dosing. This ensures precise matching of drug concentration and infection severity, effectively reducing the risk of infection aggravation due to insufficient medication or cumulative toxicity caused by overdose, and significantly improving the consistency of treatment efficacy.

This application relates to the field of biotechnology, specifically disclosing a *Pichia pastoris* yeast, its construction method, and its applications. This application involves knocking out the *gas1* gene, which is related to β-glucan synthesis, in *Pichia pastoris*. By deleting the *gas1* gene, which encodes β-glucan in the cell wall of *Pichia pastoris*, this application reduces cell size, decreases the transfer distance from the cell surface to the nucleus, improves oxygen transfer and product secretion during high-density culture, and enhances fermentation efficiency. Furthermore, the *Pichia pastoris* yeast constructed using this application enhances the synthesis of the intracellular product bisabolol and also enhances its secretion capacity. This application, by reducing cell size and decreasing the carbon flow to cell wall polysaccharide synthesis while increasing the carbon source flow to target product synthesis, has significant implications for industrial production.

The invention discloses an ultra-high molecular weight hyaluronic acid synthetase mutant as well as a construction method and application thereof, and belongs to the technical field of genetic engineering and biosynthesis. Hyaluronic acid synthetase derived from pasteurella multocida is modified by a method for constructing a random mutation library through error-prone PCR (Polymerase Chain Reaction), and a mutant, especially the mutant E401M, capable of remarkably improving the yield and molecular weight of hyaluronic acid in escherichia coli and corynebacterium glutamicum is obtained through screening. The invention provides an efficient and feasible technical approach for industrial production of the ultra-high molecular weight hyaluronic acid raw material.

The invention discloses a recombinant Pasteurella multocida-sourced uridine diphosphate glucuronide transferase (PmHS2) mutant and a preparation method thereof, and relates to the technical field of biology, the mutant is obtained by cloning a coding gene to a pET26b (+) vector, transforming BL21 (DE3) Escherichia coli competent cells, and then transforming the recombinant Pasteurella multocida-sourced uridine diphosphate glucuronide transferase (PmHS2) to a pET26b (+) vector. And carrying out IPTG (isopropyl-beta-d-thiogalactoside) induced culture, ultrasonication and nickel affinity chromatography purification to obtain high-purity protein. Compared with wild type recombinant PmHS2, the activity of N-acetyl glucosamino transferase of the mutant is improved by 70%, the residual activity is 67.1% after the mutant is stored at room temperature for 5 days, the soluble expression quantity is improved by 6 times, and the mutant and the preparation method have the advantages of high catalytic efficiency, high stability and high solubility, and the mutant and the preparation method are mature in process, controllable in cost and suitable for industrial production. The method can be efficiently used in the fields of heparin and derivative synthesis, traditional Chinese medicine active ingredient glycosylation and the like, is suitable for large-scale production and has a wide application prospect.

The application discloses a primer combination and a kit for detecting trehalose Bipartite Pasteurella, Pasteurella multocida and hemolytic Mannheimia, and belongs to the technical field of pathogenic microorganism detection. The application aims to improve the sensitivity and specificity of detection of trehalose Bipartite Pasteurella, Pasteurella multocida and hemolytic Mannheimia. The application provides a primer combination for detecting trehalose Bipartite Pasteurella, Pasteurella multocida and hemolytic Mannheimia, wherein the primer combination is primer pair 1, primer pair 2 and primer pair 3; the primer pair 1 is shown in SEQ ID NO. 1 and SEQ ID NO. 2, the primer pair 2 is shown in SEQ ID NO. 4 and SEQ ID NO. 5, and the primer pair 3 is shown in SEQ ID NO. 7 and SEQ ID NO. 8. The detection method is very stable in batch-to-batch repeatability and batch repeatability, and is suitable for large-scale clinical detection.

The invention belongs to the technical field of biological detection, and particularly relates to a dual MIRA detection method for type A clostridium botulinum and staphylococcus aureus for a portable reagent card incubator. The double colloidal gold type MIRA method established by the invention has good specificity on type A clostridium botulinum and staphylococcus aureus, and has no cross reaction with six strains such as pasteurella multocida, klebsiella pneumoniae and salmonella. The lowest detection limits of the method on the staphylococcus aureus and the A-type clostridium botulinum are 2.94 * 100 copies / mu L and 2.27 * 100 copies / mu L respectively. The optimized double colloidal gold type MIRA method can be successfully applied to a reagent card incubator. The detection method disclosed by the invention has the advantages of good specificity, high sensitivity, simplicity in operation, short time consumption and the like.

The invention belongs to the technical field of microorganisms, and particularly relates to rabbit source D-type pasteurella multocida and application thereof. The preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: M 2024856. The strain induces cellulosic pneumonia, has an application value of constructing a rabbit pasteurellosis animal model, and has good immunogenicity, a whole-cell inactivated antigen can effectively stimulate immune response of a mouse body and induce generation of a high-level antibody, and the strain has the potential of being developed into a vaccine.

This invention discloses a method for preparing and applying a Pasteurella-Bordetella nanovaccine, belonging to the field of biomedical technology. The method includes the following steps: emulsifying epigallocatechin gallate, an antigen aqueous phase, and soybean oil under high-speed shearing, followed by homogenization to form a stable oil-in-water emulsion, which is the Pasteurella-Bordetella nanovaccine. Challenge experiments confirmed that the ESO vaccine achieved a protection rate of up to 90% against Pasteurella multocida and Bordetella bronchiseptica, significantly superior to the 40%-70% protection rate of the aluminum adjuvant group. Simultaneously, it significantly reduced the bacterial load in the lungs, demonstrating excellent clinical protective effects. This invention, through the innovative combination of EGCG and vegetable oil, overcomes the limitations of traditional adjuvants in terms of immunogenicity, safety, and single function, providing a highly efficient and safe new vaccine solution for the prevention and control of Pasteurella multocida and Bordetella multocida infections.

The invention discloses dihydromyricetin copper for treating swine pasteurellosis and a preparation method of the dihydromyricetin copper. According to the method, a synthetic reaction of a complex is carried out in an ethanol-ammonium acetate buffer solution with the pH value of 3.7; the optimal feeding molar ratio of the copper salt solution to the dihydromyricetin is 1.1: 2.0; the optimal reflux reaction time is 30 minutes. The complex is stable in activity and good in antibacterial effect on pig pasteurella multocida. The invention also provides a preparation method of the complex, and the method is simple, easy to control, suitable for large-scale production, high in product yield and high in purity, and is expected to become a medicine for replacing antibiotics to treat swine pasteurellosis.

The invention discloses a fusion protein for preventing and treating various pathogenic pasteuridae bacterial infections, a nucleic acid vaccine and application of the fusion protein and the nucleic acid vaccine. The fusion protein comprises six antigens, namely rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens, namely EF-Tu, DnaK and EF-G, wherein the antigens are highly conserved in a plurality of bacteria of the pasteuridae family. The invention also provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition comprising the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection, and is used for preventing and treating infectious diseases caused by pasteurella multocida, haemophilus parasuis, Mannhemolysis Mannhema bacteria, haemophilus influenzae and haemophilus paragallinarum.

The invention relates to the technical field of genetic engineering, in particular to a pasteurella multocida waaF gene and application thereof in attenuated live vaccines. The sequence of the pasteurella multocida waaF gene is as shown in SEQ ID NO: 1, and a delta waaF gene mutant strain is highly attenuated on ducks, has a certain in-vivo colonization level and has the potential of attenuated live vaccines. The mutant strain is immunized through oral administration and intramuscular injection, so that the production performance of ducks cannot be influenced, and 81.25% and 75% of immune protection can be provided for attacking toxic substances in the lethal dose of pasteurella multocida respectively. Compared with a delta grcA attenuated strain reported in the prior art, the delta waaF mutant strain shows higher-amplitude toxicity reduction, and shows more excellent safety and balanced immune effect only at the cost of a slightly low immune protection rate.

Disclosed are novel veterinary vaccine compositions comprising a P. multocida PmSLP protein or an immunogenically equivalent portion thereof. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections of food production animals, such as bovine and porcine animals, caused by Pasteurella multocida. Related methods and uses are also disclosed.

The invention relates to the technical field of veterinary drug preparation, in particular to a bovine pasteurella multocida capsular group A disease inactivated vaccine and a preparation method thereof. The inactivated vaccine comprises an adjuvant and an antigen, wherein the antigen is a bovine pasteurella multocida capsular group A XJ strain; the antigen is a bovine pasteurella multocida capsular group A XJ strain which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 18, 2023, and is classified and named as pasteurella multocida, and the preservation number is CGMCC No.16895. When the bovine pasteurella multocida capsular group A disease inactivated vaccine is inoculated, a stable and continuous immune protection effect can be realized when the injection dosage is 2ml, and compared with the injection dosage of 4-6ml of the traditional bovine bacterial inactivated vaccine, the immune dosage is low, the clinical injection operation convenience of the vaccine is greatly improved, the vaccine packaging utilization rate is improved, and the cost is reduced. And the vaccination cost is reduced.

The application provides a kind of avian cholera multivalent subunit vaccine, multiple vaccine and its application.The avian cholera multivalent subunit vaccine in the application includes L1-plpE protein, L3-plpE protein and veterinary acceptable adjuvant;Wherein, the amino acid sequence of L1-plpE protein is SEQ ID NO.3;The amino acid sequence of L3-plpE protein is SEQ ID NO.4.In addition, the application also provides multiple vaccine, the avian cholera multivalent subunit vaccine and multiple vaccine provided by the application both have good safety, and have good protection effect to avian Pasteurella multocida A: L1 type and avian Pasteurella multocida A: L3 type avian cholera.

The invention discloses a preparation method and application of a pasteurization-bordetella nanometer vaccine, and belongs to the technical field of biological medicine. Comprising the following steps: carrying out high-speed shearing emulsification on epigallocatechin gallate, an antigen water phase and soybean oil, and homogenizing to form a stable oil-in-water emulsion, namely the pasteurization-bordetella nano vaccine. A challenge test proves that the protection rate of the ESO vaccine to pasteurella multocida and bordetella bronchiseptica reaches up to 90%, which is obviously superior to the 40-70% protection rate of an aluminum adjuvant group, and meanwhile, the lung bacterium loading amount is obviously reduced, so that the ESO vaccine shows an excellent clinical protection effect. The EGCG and the vegetable oil are innovatively compounded, so that the limitation of the traditional adjuvant in the aspects of immune efficacy, safety and function singleness is broken through, and an efficient and safe novel vaccine solution is provided for prevention and control of pasteurellosis and bordetella disease.

The invention discloses a polymyxin-gamithromycin anion liposome as well as a preparation method and application thereof. The polymyxin-gamithromycin anion liposome is composed of a lipid shell, polymyxin and gamithromycin, wherein the lipid shell is composed of anion lipid and cholesterol, and the polymyxin and the gamithromycin are wrapped in the lipid shell. Through an optimized formula, the liposome not only realizes efficient encapsulation of gamithromycin, but also effectively improves the encapsulation efficiency of polymyxin. Moreover, the optimized liposome formula can further improve the synergistic effect of the combination of polymyxin and gamithromycin, and can significantly improve the bacteriostatic and bactericidal effects on multi-drug-resistant gram-negative bacteria, especially pasteurella multocida.

The invention relates to the technical field of medical detection, in particular to a primer group for detecting common pneumonia pathogenic bacteria of forest musk deer and application of the primer group. The invention provides a primer group for detecting common pneumonia pathogenic bacteria (escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and pasteurella multocida) of forest musk deer, and successfully establishes a multiplex PCR (Polymerase Chain Reaction) method capable of simultaneously amplifying four pathogenic bacteria through a polymerase chain reaction principle. The method is high in specificity; the kit is high in sensitivity, and in a PCR reaction system of 25 microliters, the detection limit of escherichia coli is 9.2 * 10 < 4 > CFU / mL, the detection limit of klebsiella pneumoniae is 1.3 * 10 < 5 > CFU / mL, the detection limit of pseudomonas aeruginosa is 1.5 * 10 < 5 > CFU / mL, and the detection limit of pasteurella multocida is 3.7 * 10 < 4 > CFU / mL; clinical tests show that the method is good in repeatability.

This invention relates to the field of molecular diagnostics and early tumor screening technology, specifically disclosing plasma circulating microbial biomarkers for early lung cancer screening and their applications. The biomarkers include: Staphylococcus aureus, Fusobacterium nucleatum, Klebsiella pneumoniae, Alternaria incomplexa, Legionella pneumophila, Neisseria mucosa, Ralstonia pickettii, Pasteurella multocida, and Haemophilus parainfluenzae. This invention screens and combines nine specific microbial biomarkers with low-pass whole-genome sequencing technology. The WGS (World Gastroenterology) assay detects nine characteristic microbial biomarkers and uses machine learning algorithms to build a high-precision diagnostic model. The established diagnostic model has excellent stability and clinical applicability, which can not only achieve efficient identification of early lung cancer, but also significantly reduce detection costs.

The invention relates to a pasteurella multocida LAMP-CRISPR / Cas12b detection kit, the pasteurella multocida LAMP-CRISPR / Cas12b detection kit comprises an LAMP primer group, sgRNA, ssDNA, a CRISPR detection liquid containing AapCas12b protein, heparin sodium and a detection method, the detection kit can realize the combination of one-step loop-mediated isothermal amplification (LAMP) and a CRISPR / Cas12b system in a single closed reaction tube, and the detection kit can be used for detecting pasteurella multocida LAMP-CRISPR / Cas12b. The heparin sodium is introduced into a reaction system to regulate the cis-cleavage activity of Cas12b, amplification and specific recognition are integrated in the same process, operation is effectively simplified, and the pollution risk is reduced. The detection limit of the technology is 5.0232 CFU per reaction, and the technology has no cross reaction to other common bacterial species, shows high sensitivity and specificity, can be widely applied to the fields of animal epidemic disease prevention and control, food safety monitoring and public health, and is especially suitable for on-site rapid detection and pathogen nucleic acid diagnosis in a resource limited environment.

The invention relates to the technical field of microbiological detection, in particular to a CRISPR / Cas12a-based detection kit and a CRISPR / Cas12a-based detection method for detecting bovine pasteurella multocida. An isothermal amplification primer pair is designed on the basis of a conserved kmt gene of bovine pasteurella multocida, the kmt gene is subjected to amplification marking by virtue of an isothermal amplification technology, and the detection kit for detecting bovine pasteurella multocida is constructed by virtue of the high-specificity recognition capability of CRISPR / Cas12a and the visualization advantage of an immune test strip. By utilizing the detection kit and the detection method provided by the invention, the bovine pasteurella multocida can be rapidly detected under normal-temperature and constant-temperature conditions, and the detection kit and the detection method have the advantages that the result is visual and accurate, the sensitivity is high, the operation steps are simple and convenient, and large precise instruments are not needed. The kit provided by the invention is suitable for various field detection scenes such as farms and grassroots veterinary stations, and an efficient tool is provided for early prevention and control of cattle pasteurellosis.

The invention discloses a bivalent genetic engineering subunit vaccine for preventing pig pasteurella multocida and a preparation method thereof, and belongs to the field of veterinary biological products. According to the pig pasteurella multocida bivalent genetic engineering subunit vaccine disclosed by the invention, the PM recombinant protein is adopted, so that the immune effect is good, the immune dosage is small, and pig pasteurella multocida related diseases or pig pasteurella multocida infection related diseases can be effectively prevented. The preparation method disclosed by the invention is simple, can be used for preparing a large amount of pig pasteurella multocida antigen protein, is short in time consumption and high in expression quantity, greatly reduces the production cost, and is beneficial to large-scale production.

The invention belongs to the technical field of preparation of microorganisms and vaccines thereof, and relates to an F-type pasteurella multocida strain and an application of the F-type pasteurella multocida strain in preparation of vaccines, the strain is classified and named as pasteurella PmF-19 (Pasteurella sp.F-19), the strain is preserved in China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: M 20252391. The pig pasteurella multocida provided by the invention has very strong toxicity, the vaccine prepared by inactivation of the pig pasteurella multocida has good safety, the vaccine generates high-level antibodies after immunizing mice and pigs, and the vaccine has cross protection force on F and D serotype pasteurella multocida infection in the mice, and can be used for immunizing the mice and pigs. Meanwhile, complete protection of F-type strains can be provided for pigs, and the pigs can resist attack of F-type Pm lethal dose.

This invention relates to the field of biomedical technology, disclosing a broad-spectrum phage composition for the prevention and control of porcine atrophic rhinitis and its applications, particularly involving Pasteurella multocida phage SD-PM1 and Bordetella bronchiseptica phage SD-Bb1, with accession numbers CCTCC NO: M20232599 and CCTCC NO: M20232589, respectively. The phages and their compositions of this invention exhibit strong broad-spectrum lytic activity against both Pasteurella multocida and Bordetella bronchiseptica. These phages can be used alone or in combination with other phages to prepare drugs for the prevention and treatment of porcine respiratory diseases caused by single or mixed infections of Pasteurella multocida and Bordetella bronchiseptica, with particularly significant effects against porcine atrophic rhinitis. Furthermore, the phages of this invention are all virulent phages with a broad lytic spectrum, good acid and heat resistance, and can be applied in various practical scenarios.